A pivotal Phase 3 trial, VALIANT, reports a major therapeutic advancement for patients suffering from C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The study evaluated Pegcetacoplan C3G, a targeted C3 and C3b inhibitor. This drug offers a new strategy against these rare, complement-mediated kidney diseases. Historically, C3G and IC-MPGN commonly lead to irreversible renal damage. Therefore, finding an effective treatment is crucial.
Pegcetacoplan C3G Trial Results: Significant Proteinuria Reduction
The VALIANT trial enrolled 124 adolescents and adults with C3G or IC-MPGN. Importantly, the study included both native kidney disease and post-transplant recurrence patients. Consequently, researchers randomly assigned patients to receive either pegcetacoplan or a placebo. The primary endpoint focused on the log-transformed urinary protein-to-creatinine ratio (UPCR) at week 26. Pegcetacoplan showed a dramatically greater change in proteinuria compared with placebo. Specifically, the geometric mean of the UPCR decreased by 67.2%. Contrastingly, the placebo group saw an increase of 2.9%. This difference represents a substantial relative reduction of 68.1% over the placebo.
Furthermore, secondary endpoints reinforced the drug’s efficacy. A significantly higher percentage of patients in the pegcetacoplan group met the composite renal end-point criteria. This composite measure required stabilization of the estimated glomerular filtration rate (eGFR) and a ≥50% reduction in UPCR (49% vs. 3%). Also, 60% of the pegcetacoplan group achieved at least a 50% reduction in UPCR, while only 5% of the placebo group reached this benchmark. However, researchers found no significant difference between the groups in the change in the C3G histologic activity score from kidney-biopsy samples.
Understanding C3 Inhibition and Pegcetacoplan’s Mechanism
C3 glomerulopathy and IC-MPGN are driven by dysregulated activity in the complement system, especially C3 deposition. Current standard treatment relies on supportive care, such as RAAS inhibitors, and sometimes immunosuppressive drugs like mycophenolate mofetil and glucocorticoids. When these fail, C5 inhibitors like eculizumab are occasionally considered. Pegcetacoplan, however, acts earlier in the complement cascade. It is a targeted C3 and C3b inhibitor. Thus, it modulates complement overactivation at a central point, which distinguishes it from C5 inhibitors. Furthermore, C3 inhibition can address both intravascular and extravascular pathology. This mechanism provides a comprehensive blockade of the complement pathway.
Safety Profile and Clinical Implications
The safety profile of pegcetacoplan appeared comparable to placebo. Investigators reported no increase in adverse events. Crucially, the trial saw no serious infections from encapsulated bacteria. One patient in the pegcetacoplan group died from COVID-19 pneumonia, but this was unrelated to the study drug. Additionally, the study did not observe any allograft rejection or loss in transplanted patients. Ultimately, the results confirm that pegcetacoplan significantly reduces proteinuria in patients with C3G or IC-MPGN. This offers a compelling, targeted complement-inhibition strategy for this high-risk population.
Frequently Asked Questions
Q1: What is the mechanism of action for pegcetacoplan?
Pegcetacoplan acts as a targeted inhibitor of complement protein C3 and its fragment C3b. This action is central in the complement cascade, preventing the downstream damage that characterizes C3 glomerulopathy and IC-MPGN.
Q2: What was the key finding of the Phase 3 VALIANT trial?
The trial found that pegcetacoplan achieved a 68.1% relative reduction in the urinary protein-to-creatinine ratio (UPCR) compared to placebo at week 26.
Q3: Does C3 Glomerulopathy commonly recur after kidney transplant?
Yes, C3G carries a high risk of histological recurrence following kidney transplantation. The VALIANT trial included patients with post-transplant disease recurrence and found positive results.
References
- Fakhouri F et al. Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN. N Engl J Med. 2025 Dec 04. doi: 10.1056/NEJMoa2501510. PMID: 41337715.
- Goodship, Timothy H J et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a KDIGO Controversies Conference. Kidney intl vol. 91,3 (2017): 539-551.
- National Kidney Foundation. Complement 3 Glomerulopathy (C3G).
- Apellis Pharmaceuticals. Apellis’ EMPAVELI Shows 68% Reduction in Proteinuria for Rare Kidney Diseases. Investing.com. 2025 Dec 04.